

Changes to the Medi-Cal Rx Contract Drugs List

July 1, 2024

The below changes have been made to the <u>Medi-Cal Rx Contract Drugs List</u> and the

^{*} Medi-Cal Rx Diagnosis Crosswalk posted to the Medi-Cal Rx Web Portal, effective July 1, 2024.

Drug Name	Description	Effective Date
Baricitinib	* Added to the <i>Medi-Cal Rx Contract Drugs List</i> (CDL) with diagnosis and labeler restriction.	July 1, 2024
Bismuth Subcitrate Potassium/Metronidazole/ Tetracycline HCL	Labeler restriction removed.	July 1, 2024
Contraceptives	Quantity limit (QL) updated on tablets, vaginal ring, and transdermal patches.	July 1, 2024
Insulin Lispro Protamine 50% and Insulin Lispro 50%	Vial end-dated.	July 1, 2024
Loteprednol Etabonate/Tobramycin	Labeler restriction added.	July 1, 2024
Methadone HCL	Added to the CDL.	July 1, 2024
Nitazoxanide	Added to the CDL.	July 1, 2024
Quetiapine Fumarate	Additional strength (150 mg) added to the CDL.	July 1, 2024
Tovorafenib	Added to the CDL with prior authorization (PA) required.	July 1, 2024
Vortioxetine hydrobromide	Labeler restriction added.	July 1, 2024

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.

Changes to the CDL 07/01/2024